Review of the use of neuraminidase inhibitors for prophylaxis of influenza.

H. A. Kirkbride*, J. Watson

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)


Influenza causes significant morbidity and mortality particularly in vulnerable population groups. Although vaccination is recommended as the primary method of preventing influenza, antiviral drugs may play a complementary role. The National Institute for Clinical Effectiveness (NICE) has recently published guidance on the use of anti-viral drugs in the treatment of influenza, and further guidance on their use for prophylaxis is expected later in the year. In anticipation of this guidance this paper reviews the evidence for the effectiveness of the prophylactic use of neuraminidase inhibitors. Results of this review show that neuraminidase inhibitors are effective in preventing laboratory-confirmed clinical influenza in healthy adults, both when used as post-exposure prophylaxis for close and household contacts, and as seasonal prophylaxis in the wider community. Direct evidence in the elderly and institutions is too limited to draw firm conclusions about their effectiveness in that setting. However it seems probable that neuraminidase inhibitors would also be effective in these groups.

Original languageEnglish
Pages (from-to)123-127
Number of pages5
JournalCommunicable disease and public health / PHLS
Issue number2
Publication statusPublished - Jun 2003


Dive into the research topics of 'Review of the use of neuraminidase inhibitors for prophylaxis of influenza.'. Together they form a unique fingerprint.

Cite this